- Home
- BIRD vs UNCY Comparison
BIRD vs UNCY Comparison
Compare BIRD & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIRD
- UNCY
- Stock Information
- Founded
- BIRD 2015
- UNCY 2016
- Country
- BIRD United States
- UNCY United States
- Employees
- BIRD N/A
- UNCY N/A
- Industry
- BIRD Apparel
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- BIRD Consumer Discretionary
- UNCY Health Care
- Exchange
- BIRD Nasdaq
- UNCY Nasdaq
- Market Cap
- BIRD 89.7M
- UNCY 74.2M
- IPO Year
- BIRD 2021
- UNCY 2021
- Fundamental
- Price
- BIRD $6.13
- UNCY $3.87
- Analyst Decision
- BIRD Buy
- UNCY Strong Buy
- Analyst Count
- BIRD 2
- UNCY 4
- Target Price
- BIRD $11.00
- UNCY $63.75
- AVG Volume (30 Days)
- BIRD 49.9K
- UNCY 515.8K
- Earning Date
- BIRD 11-05-2025
- UNCY 11-12-2025
- Dividend Yield
- BIRD N/A
- UNCY N/A
- EPS Growth
- BIRD N/A
- UNCY N/A
- EPS
- BIRD N/A
- UNCY N/A
- Revenue
- BIRD $170,646,000.00
- UNCY N/A
- Revenue This Year
- BIRD N/A
- UNCY N/A
- Revenue Next Year
- BIRD $4.20
- UNCY $3,131.28
- P/E Ratio
- BIRD N/A
- UNCY N/A
- Revenue Growth
- BIRD N/A
- UNCY N/A
- 52 Week Low
- BIRD $3.93
- UNCY $3.40
- 52 Week High
- BIRD $14.20
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- BIRD 36.32
- UNCY 34.49
- Support Level
- BIRD $5.93
- UNCY $4.23
- Resistance Level
- BIRD $6.32
- UNCY $4.43
- Average True Range (ATR)
- BIRD 0.34
- UNCY 0.20
- MACD
- BIRD 0.09
- UNCY -0.00
- Stochastic Oscillator
- BIRD 18.18
- UNCY 8.20
About BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.